Abstract
Adeno-associated virus (AAV)-based vectors belong to the most promising gene transfer vectors in clinical studies. To provide vector for late-stage clinical trials as well as for a potential commercial phase, a scalable, cGMP-compliant process is required. Nearly all vector production protocols currently approved in Phase I clinical trials rely on AAV production in adherent HEK 293 cells in the presence of serum. In this study, we present a helper- and serum-free production method of AAV vectors in suspension-adapted HEK 293 cells. The method is based on plasmid transfection with 25 kDa linear polyethyleneimine. Compared to existing methods, our system is highly scalable as cells grow in suspension, does not require animal-derived products or the use of an exogenous virus (adenovirus or baculovirus) and yields genomic titers equal to those obtained in adherent HEK 293 cells in the presence of serum. Most importantly, work load and cost could be dramatically reduced in comparison to earlier methods, when comparing the production of equivalent volumes of cell culture media. Thus, our protocol should appeal to both basic research laboratories and cGMP manufacturing units.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Auricchio A, Hildinger M, O’Connor E, Gao GP, Wilson JM (2001) Isolation of highly infectious and pure adeno-associated virus type 2 vectors with a single-step gravity-flow column. Hum Gene Ther 12(1):71–76
Baldi L, Muller N, Picasso S, Jacquet R, Girard P, Thanh HP, Derow E, Wurm FM (2005) Transient gene expression in suspension HEK-293 cells: application to large-scale protein production. Biotechnol Prog 21(1):148–153
Booth MJ, Mistry A, Li X, Thrasher A, Coffin RS (2004) Transfection-free and scalable recombinant AAV vector production using HSV/AAV hybrids. Gene Ther 11(10):829–837
Brightwell G, Poirier V, Cole E, Ivins S, Brown KW (1997) Serum-dependent and cell cycle-dependent expression from a cytomegalovirus-based mammalian expression vector. Gene 194(1):115–123
Conway JE, Rhys CM, Zolotukhin I, Zolotukhin S, Muzyczka N, Hayward GS, Byrne BJ (1999) High-titer recombinant adeno-associated virus production utilizing a recombinant herpes simplex virus type I vector expressing AAV-2 Rep and Cap. Gene Ther 6(6):986–993
Durocher Y, Perret S, Thibaudeau E, Gaumond MH, Kamen A, Stocco R, Abramovitz M (2000) A reporter gene assay for high-throughput screening of G-protein-coupled receptors stably or transiently expressed in HEK293 EBNA cells grown in suspension culture. Anal Biochem 284(2):316–326
Farson D, Harding TC, Tao L, Liu J, Powell S, Vimal V, Yendluri S, Koprivnikar K, Ho K, Twitty C, Husak P, Lin A, Snyder RO, Donahue BA (2004) Development and characterization of a cell line for large-scale, serum-free production of recombinant adeno-associated viral vectors. J Gene Med 6(12):1369–1381
Florea BI, Meaney C, Junginger HE, Borchard G (2002) Transfection efficiency and toxicity of polyethylenimine in differentiated Calu-3 and nondifferentiated COS-1 cell cultures. AAPS PharmSci 4(3):E12
Gao GP, Lu F, Sanmiguel JC, Tran PT, Abbas Z, Lynd KS, Marsh J, Spinner NB, Wilson JM (2002) Rep/Cap gene amplification and high-yield production of AAV in an A549 cell line expressing Rep/Cap. Mol Ther 5(5 Pt 1):644–649
Li C, Samulski RJ (2005) Serotype-specific replicating AAV helper constructs increase recombinant AAV type 2 vector production. Virology 335(1):10–21
Li C, Bowles DE, van Dyke T, Samulski RJ (2005) Adeno-associated virus vectors: potential applications for cancer gene therapy. Cancer Gene Ther
Liu X, Voulgaropoulou F, Chen R, Johnson PR, Clark KR (2000) Selective Rep-Cap gene amplification as a mechanism for high-titer recombinant AAV production from stable cell lines. Mol Ther 2(4):394–403
Mandel RJ, Burger C (2004) Clinical trials in neurological disorders using AAV vectors: promises and challenges. Curr Opin Mol Ther 6(5):482–490
Maxwell F, Harrison GS, Maxwell IH (1997) Improved production of recombinant AAV by transient transfection of NB324K cells using electroporation. J Virol Methods 63(1–2):129–136
Muller N, Girard P, Hacker DL, Jordan M, Wurm FM (2005) Orbital shaker technology for the cultivation of mammalian cells in suspension. Biotechnol Bioeng 89(4):400–406
Samulski RJ (2003) AAV vectors, the future workhorse of human gene therapy. Ernst Schering Res Found Workshop (43):25–40
Stratagene (2004) AAV Helper-Free System
Urabe M, Ding C, Kotin RM (2002) Insect cells as a factory to produce adeno-associated virus type 2 vectors. Hum Gene Ther 13(16):1935–1943
Vincent KA, Piraino ST, Wadsworth SC (1997) Analysis of recombinant adeno-associated virus packaging and requirements for rep and cap gene products. J Virol 71(3):1897–1905
Acknowledgement
This work was financially supported by a KTI-grant obtained from the Swiss government.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hildinger, M., Baldi, L., Stettler, M. et al. High-titer, serum-free production of adeno-associated virus vectors by polyethyleneimine-mediated plasmid transfection in mammalian suspension cells. Biotechnol Lett 29, 1713–1721 (2007). https://doi.org/10.1007/s10529-007-9441-3
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10529-007-9441-3